# Karen-Lise G Spindler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1811808/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 49 papers | 1,520 citations | 430874 18 h-index | 315739 38 g-index |
| 50 all docs | 50 docs citations | 50 times ranked | 2554 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases â€“ a report from the Danish Anal Cancer Group. Acta OncolÃ³gica, 2022, 61, 321-327. | 1.8 | 1 |
| 2 | Total cellâ€‘free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay. Molecular and Clinical Oncology, 2022, 16, 64. | 1.0 | 2 |
| 3 | A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer. Cancers, 2022, 14, 1697. | 3.7 | 7 |
| 4 | â€œGlobal Multidisciplinary Team Meetingsâ€: Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). Clinical Colorectal Cancer, 2022, , . | 2.3 | 1 |
| 5 | Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. British Journal of Cancer, 2022, 127, 500-513. | 6.4 | 15 |
| 6 | Hypoxia and local tumour control in squamous cell carcinoma of the anus â€“ a hypothesis-generating study. Acta OncolÃ³gica, 2022, 61, 1132-1135. | 1.8 | 1 |
| 7 | Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. Radiotherapy and Oncology, 2021, 157, 141-146. | 0.6 | 4 |
| 8 | Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp>RAS</scp>â€mutated or <scp>BRAF</scp>â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397. | 5.1 | 10 |
| 9 | The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers, 2021, 13, 2451. | 3.7 | 25 |
| 10 | Nonplatinumâ€based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A populationâ€based Danish anal cancer group study. Cancer Medicine, 2021, 10, 3224-3230. | 2.8 | 2 |
| 11 | Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anusâ€”A Population-Based Experience from the Danish Anal Cancer Group. Cancers, 2021, 13, 3226. | 3.7 | 3 |
| 12 | Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical Colorectal Cancer, 2021, 20, 279-287. | 2.3 | 6 |
| 13 | Management of late adverse effects after chemoradiation for anal cancer. Acta OncolÃ³gica, 2021, 60, 1688-1701. | 1.8 | 4 |
| 14 | Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta OncolÃ³gica, 2020, 59, 1016-1023. | 1.8 | 8 |
| 15 | Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. Acta OncolÃ³gica, 2020, 59, 1424-1429. | 1.8 | 18 |
| 16 | A melt-electrowritten filter for capture and culture of circulating colon cancer cells. Materials Today Bio, 2020, 6, 100052. | 5.5 | 8 |
| 17 | Mesorectal radiotherapy for early stage rectal cancer: A novel target volume. Clinical and Translational Radiation Oncology, 2020, 21, 104-111. | 1.7 | 10 |
| 18 | Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence. Radiotherapy and Oncology, 2020, 150, 211-216. | 0.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. Molecular and Clinical Oncology, 2020, 13, 1-1. | 1.0 | 6 |
| 20 | Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. Scientific Reports, 2019, 9, 11542. | 3.3 | 25 |
| 21 | Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer â€“ A multicentre dose planning study. Technical Innovations and Patient Support in Radiation Oncology, 2019, 11, 14-21. | 1.9 | 12 |
| 22 | Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review. Clinical and Translational Oncology, 2019, 21, 874-880. | 2.4 | 8 |
| 23 | Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. Tumor Biology, 2018, 40, 101042831881120. | 1.8 | 10 |
| 24 | KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark. Acta OncolÃ³gica, 2018, 57, 1727-1729. | 1.8 | 0 |
| 25 | Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization. Radiotherapy and Oncology, 2018, 128, 375-379. | 0.6 | 21 |
| 26 | Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. Translational Oncology, 2018, 11, 1220-1224. | 3.7 | 63 |
| 27 | Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta OncolÃ³gica, 2017, 56, 7-16. | 1.8 | 33 |
| 28 | Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncologist, 2017, 22, 1049-1055. | 3.7 | 73 |
| 29 | Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biology, 2017, 39, 101042831773097. | 1.8 | 18 |
| 30 | Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. BMJ Open, 2017, 7, e019474. | 1.9 | 87 |
| 31 | KRAS testing practice in Denmark between 2009 and 2013.. Journal of Clinical Oncology, 2017, 35, 654-654. | 1.6 | 0 |
| 32 | Systematic review: brain metastases from colorectal cancerâ€"Incidence and patient characteristics. BMC Cancer, 2016, 16, 260. | 2.6 | 82 |
| 33 | Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. British Journal of Cancer, 2016, 114, 96-102. | 6.4 | 17 |
| 34 | Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0108247. | 2.5 | 109 |
| 35 | TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. Tumor Biology, 2015, 36, 4301-4308. | 1.8 | 7 |
| 36 | Controls to validate plasma samples for cell free DNA quantification. Clinica Chimica Acta, 2015, 446, 141-146. | 1.1 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. European Journal of Cancer, 2015, 51, 2678-2685. | 2.8 | 48 |
| 38 | Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. Clinica Chimica Acta, 2015, 439, 97-101. | 1.1 | 33 |
| 39 | Reirradiation of locally recurrent rectal cancer: A systematic review. Radiotherapy and Oncology, 2014, 113, 151-157. | 0.6 | 102 |
| 40 | Changes in mutational status during thirdâ€line treatment for metastatic colorectal cancerâ€"Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. International Journal of Cancer, 2014, 135, 2215-2222. | 5.1 | 76 |
| 41 | Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. International Journal of Cancer, 2014, 135, 2984-2991. | 5.1 | 94 |
| 42 | A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer. Colorectal Cancer, 2014, 3, 135-145. | 0.8 | 3 |
| 43 | Contact therapy: A feasible option for local treatment of rectal cancer in non-operable patientsâ€"A Danish experience.. Journal of Clinical Oncology, 2014, 32, e14543-e14543. | 1.6 | 0 |
| 44 | Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls, and non-cancer patients with comorbidity.. Journal of Clinical Oncology, 2014, 32, 3559-3559. | 1.6 | 9 |
| 45 | Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. Anticancer Research, 2014, 34, 845-50. | 1.1 | 14 |
| 46 | Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma. Acta OncolÃ³gica, 2013, 52, 963-970. | 1.8 | 56 |
| 47 | Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancerâ€"Results of a Phase II and Translational Research Study. Journal of Cancer Therapy, 2013, 04, 44-50. | 0.4 | 4 |
| 48 | Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clinical Cancer Research, 2012, 18, 1177-1185. | 7.0 | 244 |
| 49 | The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Annals of Oncology, 2009, 20, 879-884. | 1.2 | 72 |